Please ensure Javascript is enabled for purposes of website accessibility
Accueil > Products > Anticorps > Biosimilaires

Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO) (HS856076)

Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)
Prix(USD) :
Spécification :
  • 100ug
  • 1mg
  • 5mg
  • 10mg
  • 25mg
  • 50mg
  • 100mg
Nombre :
Contactez-nous
  • Aperçu

  • Images

  • Reférences

  • Fiche technique

  • SDS

Aperçu
Numéro de catalogueHS856076
Description
Research Grade Afasevikumab (HS856076) is a human monoclonal antibody detecting CTLA-8 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights
  • ●Multi-Application — Validated across multiple applications.
Reactivité des espècesHuman
ApplicationsELISA, Bioactivity: FCM, Functional assay, Research in vivo
Espèce hôteHuman
ClonalitéMonoclonal
IsotypeIgG1-kappa
Cible CTLA-8, CTLA8, Cytotoxic T-lymphocyte-associated antigen 8, IL-17, IL-17A, IL17, IL17A, Interleukin-17A, Cytokine ML-1, IL-17F, IL17F, Interleukin-17F
Niveau d'endotoxines < 10 EU/mg
Pureté >95% as determined by SDS-PAGE.
Purification Protein A/G purified from cell culture supernatant.
Numéro d'accès Q16552, Q96PD4
Forme Liquid
Tampon de stockage 0.01M PBS pH 7.4.

Reférez-vous aux informations spécifiques sur le tampon dans la copie papier du datasheet ou dans le COA spécifique au lot.

Stabilité et stockage Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Noms alternatifsMCAF-5352A, MCAF5352A, NI-1401, RG-7624, RG7624, RO5553110, 1589503-30-9
ContexteAfasevikumab, also known as RG7624, is a human antibody inhibitor for human interleukin 17A (IL17A) and interleukin 17F (IL17F). This drug was developed by Genentech and has been investigated in the study of the treatment of inflammation diseases like autoimmune disorders. In 2013, Genentech completed a phase Ib study for the treatment of autoimmune disorders in Canada. However, it had been discontinued in 2015. In 2016, researchers used afasevikumab to conduct a phase I clinical trials for the treatment of inflammation in USA with no specified.
• IL-17 and IL-17-producing cells in protection versus pathology., PMID:35790881
• The IL-17 Family of Cytokines in Health and Disease., PMID:30995505
• The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond., PMID:30127781
• Functional specialization of interleukin-17 family members., PMID:21349428
• Serum Amyloid A Proteins Induce Pathogenic Th17 Cells and Promote Inflammatory Disease., PMID:31866067
• The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases., PMID:37600764
• The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis., PMID:30109481
• Pathogenic Role of IL-17 and Therapeutic Targeting of IL-17F in Psoriatic Arthritis and Spondyloarthropathies., PMID:37373452
• Rhythmic IL-17 production by γδ T cells maintains adipose de novo lipogenesis., PMID:39478228
• Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation., PMID:29275332
Note For research use only. Not suitable for clinical or therapeutic use.
Isotype Control Human IgG1 Recombinant Isotype Control Antibody (HyHEL-10) (HV080407)
Human IgG1 Recombinant Isotype Control Antibody (13R4) (HV080507)
Images
  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)

    SEC-HPLC

    SEC-HPLC detection for Research Grade Afasevikumab.

  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)

    Bioactivity

    Detects IL17A in indirect ELISAs.

  • Anti-Human IL-17A/F Heterodimer Reference Antibody (Afasevikumab, RUO)

    SDS-PAGE

    SDS-PAGE for Research Grade Afasevikumab.

Reférences
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
Recommandation

Contactez-nous pour les devis personnalisés, les demandes en gros et tout autre problème.

Courrier : [email protected]

Liste des distributeurs